The TB laboratory of the future: Macrophage based selection of XDR-TB therapeutics

Future Microbiology

Volumn 3, Issue 2, 2008, Pages 135-144

  Martins, Marta ^a   Viveiros, Miguel ^a   Amaral, Leonard ^a  

^a INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

Author keywords

Derivatives; K+ inhibition; Macrophages; MDR TB; Mycobacterium tuberculosis; Phenothiazines; Thioridazine; XDR TB

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CAPREOMYCIN; ISONIAZID; KANAMYCIN; METHANOL DERIVATIVE; PHENOTHIAZINE; RIFAMPICIN; SILICONE DERIVATIVE; THIORIDAZINE; THIORIDAZINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; CLINICAL LABORATORY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRACELLULAR KILLING; LUNG ALVEOLUS MACROPHAGE; LUNG TUBERCULOSIS; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATIENT CARE; PHAGOCYTOSIS; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTITUBERCULAR AGENTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; MACROPHAGES; MACROPHAGES, ALVEOLAR; MYCOBACTERIUM TUBERCULOSIS; PHAGOCYTOSIS;

BACTERIA (MICROORGANISMS); MYCOBACTERIUM TUBERCULOSIS;

EID: 47249116969     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460913.3.2.135     Document Type: Article

References (40)

1. World Health Organization Report 2007 - Global tuberculosis control surveillance, planning, financing. World Health Organization. Geneva, Switzerland (2007).
2. Report of the meeting of the WHO Global Task Force on XDR-TB. World Health Organization. Geneva, Switzerland, 9-10 October (2006).
3. Centers for Disease Control and Prevention (CDC): Extensively drug-resistant tuberculosis-United States, 1993-2006. MMWR Morb. Mortal. Wkly Rep. 56 (11), 250-253 (2007).
4. Shah NS, Wright A, Bai GH et al.: Worldwide emergence of extensively drug-resistant tuberculosis. Emerg. Infect. Dis. 13(3), 380-387 (2007).
5. Goldman RC, Plumley KV, Laughon BE: The evolution of extensively drug resistant tuberculosis (XDR-TB): history, status and issues for global control. Infect. Disord. Drug Targets 7 (2), 73-91 (2007).
6. Spigelman MK: New tuberculosis therapeutics: a growing pipeline. J. Infect. Dis. 196(Suppl. 1), S28-S34 (2007).
7. Amaral L, Viveiros M, Kristiansen JE: 'Non-antibiotics': alternative therapy for the management of MDRTB and MRSA in economically disadvantaged countries. Curr. Drug Targets 7(7), 887-891 (2006).
8. Amaral L, Martins M, Viveiros M: Phenothiazines as anti-multi-drug resistant tubercular agents. Infect. Disord. Drug Targets 7(3), 257-265 (2007).
9. Amaral L, Martins M, Viveiros M: Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps. J. Antimicrob. Chemother. 59(6), 1237-1246 (2007).
10. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW: The emergence of drug-resistant tuberculosis in New York City. N. Engl. J. Med. 328(8), 521-526 (1993).
11. Parsons LM, Somoskövi A, Urbanczik R, Salfinger M: Laboratory diagnostic aspects of drug resistant tuberculosis. Front. Biosci. 9, 2086-2105 (2004).
12. Hale YM, Pfyffer GE, Salfinger M: Laboratory diagnosis of mycobacterial infections: new tools and lessons learned. Clin. Infect Dis. 33 (6), 834-846 (2001).
13. Antunes ML, Aleixo-Dias J, Antunes MF, Pereira MF, Raymundo E, Rodrigues MF: Anti-tuberculosis drug resistance in Portugal. Int. J. Tuberc. Lung. Dis. 4(3), 223-231 (2000).
14. Viveiros M, Leandro C, Rodrigues L et al.: Direct application of the INNO-LiPA Rif.TB line-probe assay for rapid identification of Mycobacterium tuberculosis complex strains and detection of rifampin resistance in 360 smear-positive respiratory specimens from an area of high incidence of multidrug-resistant tuberculosis. J. Clin. Microbiol. 43(9), 4880-4884 (2005).
15. Sam IC, Drobniewski F, More P, Kemp M, Brown T: Mycobacterium tuberculosis and rifampin resistance, United Kingdom. Emerg. Infect. Dis. 12(5), 752-759 (2006).
16. Direção Geral de Saúde: Programa Nacional De Luta Contra A Tuberculose (PNT). Ponto da Situação Epidemiológica e de Desempenho Ano 2006, 1-12. DGS, Lisboa, Portugal (2007).
17. Amaral L, Viveiros M, Molnar J: Antimicrobial activity of phenothiazines. In vivo 18(6), 725-732 (2004).
18. Saunders BM, Britton WJ: Life and death in the granuloma: immunopathology of tuberculosis. Immunol. Cell/Biol. 85(2), 103-111 (2007).
19. Ordway D, Viveiros M, Leandro C et al.: Chlorpromazine has intracellular killing activity against phagocytosed Staphylococcus aureus at clinical concentrations. J. Infect. Chemother. 8(3), 227-231 (2002).
20. Ordway D, Viveiros M, Leandro C et al.: Clinical concentrations of thioridazine kill intracellular multi-drug resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47(3), 917-922 (2003).
21. Ordway D, Viveiros M, Leandro C, Arroz MJ, Amaral L: Intracellular activity of clinical concentrations of phenothiazines including thioridazine against phagocytosed Staphylococcus aureus. Int. J. Antimicrob. Agents. 20(1), 34-43 (2002).
22. Daniel WA, Wojcikowski J: The role of lysosomes in the cellular distribution of thioridazine and potential drug interactions. Toxicol. Appl. Pharmacol. 158(2), 115-124 (1999).
23. Martins M, Bleiss W, Marko A et al.: Clinical concentrations of thioridazine enhance the killing of intracellular methicillin-resistant Staphylococcus aureus. an in vivo, ex vivo and electron microscopy study. In vivo 18(6), 787-794 (2004).
24. Martins M, Viveiros M, Kristiansen JE, Molnar J, Amaral L: The curative activity of thioridazine on mice infected with Mycobacterium tuberculosis. In vivo 21, 771-776 (2007).
25. Martins M, Ordway D, Kristiansen M et al.: Inhibition of the Carpobrotus edulis methanol extract on the growth of phagocytosed multidrug-resistant Mycobacterium tuberculosis and methicillin-resistant Staphylococcus aureus. Fitoterapia 76(1), 96-99 (2005).
26. Ordway D, Hohmann J, Viveiros M et al.: Carpobrotus edulis methanol extract inhibits the MDR efflux pumps, enhances killing of phagocytosed S. aureus and promotes immune modulation. Phytother. Res. 17(5), 512-519 (2003).
27. Martins M, Schelz Z, Martins A et al.: In vitro and ex vivo activity of thioridazine derivatives against. Mycobacterium tuberculosis. Int. J. Antimicrob. Agents. 29(3). 338-340 (2007).
28. Guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization. Geneva, Switzerland (2006).
29. Pai M, Kalantri S, Dheda K: New tools and emerging technologies for the diagnosis of tuberculosis: part II. Active tuberculosis and drug resistance. Expert. Rev. Mol. Diagn. 6(3), 423-432 (2006).
30. Palomino JC: Newer diagnostics for tuberculosis and multi-drug resistant tuberculosis. Curr. Opin. Pulm. Med. 12(3), 172-178 (2006).
31. Migliori GB, Loddenkemper R, Blasi F, Raviglione MC: 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is 'science' enough to tackle the epidemic? Eur. Respir. J. 29(3), 423-427 (2007).
32. Hamilton CD, Sterling TR, Blumberg HM et al.: Extensively drug-resistant tuberculosis: are we learning from history or repeating it? Clin. Infect. Dis. 45, 338-342 (2007).
33. + efflux pumps of the bacterium and the killing macrophage. Anti-Infective Agents In Medicinal Chemistry 7, 63-72 (2008).
34. Lemaire S, Van Bambeke F, Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM: Role of acidic pH in the susceptibility of intraphagocytic methicillin-resistant Staphylococcus aureus strains to meropenem and cloxacillin. Antimicrob. Agents Chemother. 51(5), 1627-1632 (2007).
35. Baudoux P, Bles N, Lemaire S, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F: Combined effect of pH and concentration on the activities of gentamicin and oxacillin against Staphylococcus aureus in pharmacodynamic models of extracellular and intracellular infections. J. Antimicrob. Chemother. 59(2), 246-253 (2007).
36. Barcia-Macay M, Lemaire S, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F: Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 58(6), 1177-1184 (2006).
37. Matteelli A, Migliori GB, Cirillo D, Centis R, Girard E, Raviglion M: Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control. Expert. Rev. Anti Infect. Ther. 5(5), 857-871 (2007).
38. Yew WW, Leung CC: Management of multidrug-resistant tuberculosis: Update 2007. Respirology. 13(1), 21-46 (2008).
39. Sungkanuparph S, Eampokalap B, Chottanapund S, Thongyen S, Manosuthi W: Impact of drug-resistant tuberculosis on the survival of HIV-infected patients. Int. J. Tuberc. Lung Dis. 11(3), 325-330 (2007).
40. Ormerod LP: Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment. British Med. Bull. 73-74, 17-24 (2005).